Format

Send to

Choose Destination
J Oncol Pharm Pract. 2012 Sep;18(3):360-5. doi: 10.1177/1078155212438252. Epub 2012 Feb 29.

Silybum marianum (milk thistle) in the management and prevention of hepatotoxicity in a patient undergoing reinduction therapy for acute myelogenous leukemia.

Author information

1
Arthur G. James Cancer Hospital, The Ohio State University Department of Pharmacy, Columbus, OH 43210, USA. alimcbride@gmail.com

Abstract

Hepatotoxicity has been observed with several chemotherapy agents and combination regimens. Conventional treatment methods often include supportive care or observation. We report a case of a patient with noted transaminitis presumed secondary to chemotherapy, which did not resolve with supportive care but was shown to respond to milk thistle. The patient had an immediate decrease in liver function tests and showed decreased elevation in levels upon treatment with subsequent chemotherapy regimens. This case demonstrates the potential efficacy of milk thistle as a unique hepatoprotective agent.

PMID:
22378810
DOI:
10.1177/1078155212438252
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center